{"organizations": [], "uuid": "fd733da428cd81e0e6dd9f9199c11a5d0f972fcf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180208.html", "section_title": "Archive News &amp; Video for Thursday, 08 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-molecular-partners-fy-net-loss-of/brief-molecular-partners-fy-net-loss-of-chf-25-4-million-idUSFWN1PY0DY", "country": "US", "domain_rank": 408, "title": "BRIEF-Molecular Partners FY Net Loss Of CHF 25.4 Million", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.002, "site_type": "news", "published": "2018-02-08T14:16:00.000+02:00", "replies_count": 0, "uuid": "fd733da428cd81e0e6dd9f9199c11a5d0f972fcf"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-molecular-partners-fy-net-loss-of/brief-molecular-partners-fy-net-loss-of-chf-25-4-million-idUSFWN1PY0DY", "ord_in_thread": 0, "title": "BRIEF-Molecular Partners FY Net Loss Of CHF 25.4 Million", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "allergan", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 8 (Reuters) - MOLECULAR PARTNERS AG:\n* 2017 FINANCIAL PERFORMANCE IN-LINE WITH EXPECTATIONS AND GUIDANCE\n* MOLECULAR PARTNERS-ONGOING STRONG FINANCIAL POSITION WITH CHF 141.1 MILLION IN CASH AND SHORT-TERM TIME DEPOSITS AS OF DEC 31, 2017\n* NET CASH USED IN OPERATING ACTIVITIES OF CHF 40.0 MILLION IN 2017\n* OPERATING LOSS OF CHF 25.8 MILLION AND NET LOSS OF CHF 25.4 MILLION IN 2017\n* ABICIPAR: ALLERGAN ON TRACK TO PRESENT ONE-YEAR PHASE 3 EFFICACY DATA IN H2 2018\n* JÃ–RN ALDAG, CURRENT CHAIRMAN, INDICATED WISH NOT TO STAND FOR RE-ELECTION AT THE 2018 AGM\n* FOR THE FULL YEAR 2018, AT CONSTANT EXCHANGE RATES, CO EXPECTS TOTAL EXPENSES OF CHF 50-60 MILLION\n* NO GUIDANCE CAN BE PROVIDED WITH REGARD TO NET CASH FLOW PROJECTIONS Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-08T14:16:00.000+02:00", "crawled": "2018-02-09T17:10:32.010+02:00", "highlightTitle": ""}